Vilon: A Peptide Bioregulator Research Overview
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
- Vilon is a very short two-amino-acid peptide studied as a bioregulator, mainly in Russian aging and immune research.
- The evidence is largely preclinical and animal-based with little independent human data, so it is early-stage.
- Online discussion is unverified anecdote, not proof.
- It is not approved for human or veterinary use, and nothing here is medical advice.
- BioRegen supplies Vilon strictly for laboratory and educational research.
Vilon is a very small lab-made peptide. A peptide is just a short chain of amino acids, the building blocks of proteins. Vilon is made of only two of them, lysine and glutamic acid, which is why it is written as Lys-Glu. It is part of a group called "peptide bioregulators" that Russian research teams have studied for many years. This page sums up what scientists have looked at so far and points out that the work is still in its early days. All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
What is Vilon?
Vilon is the two-part peptide Lys-Glu, also shortened to KE. Researchers study it as something that may help turn certain genes on or off and may affect how cells behave. In science papers it is often listed alongside other "Khavinson peptides," a set of very short peptides that scientists are looking into for their possible roles in how cells send signals and regulate themselves in lab studies.
What the research explores
Studies on short peptides like Lys-Glu have looked at how they affect genes tied to cell aging and to the way cells mature into different types. This work is done on cells grown in dishes, not in people. For example, some studies reported that short peptides can change the activity of aging-related genes in human stem cell cultures [2], and may affect signs that stem cells are turning into nerve cells [1]. Keep in mind this is an early field. Most of the evidence so far comes from lab dishes and animals, not from human trials.
Research handling considerations
Like most short peptides, Vilon usually ships as a dry powder. In the lab, researchers mix it back into a liquid before working with it. For general background on how labs handle that step, see our peptide reconstitution guide. These are general lab-handling notes only. They are not directions for use in people or animals.
Frequently asked questions
What kind of peptide is Vilon?
Vilon is a two-part peptide made of lysine and glutamic acid (Lys-Glu). It is one of the smallest peptide bioregulators that scientists have studied.
Is the research conclusive?
No. The research is still early, and most of it has been done in lab dishes and animals rather than in people. So the findings should be read as early hints, not as settled answers.
Selected research references
- [1] Caputi S, et al. (2019). Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. doi:10.1177/2058738419828613
- [2] Ashapkin V, et al. (2020). Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep. doi:10.1007/s11033-020-05506-3
Reference metadata sourced via PubMed.
Explore compounds studied in immune research in our IMMUNITY collection, or use the Research Finder to navigate by goal. Join the research list for 10% off your first order by creating a free account.
Disclaimer: All products and information provided by BioRegen are for laboratory and educational research purposes only. Nothing here is medical advice, and no compound referenced is approved for human or veterinary use.